Solid Biosciences, Inc. (NASDAQ: SLDB)

DEFENDANT NAME: Solid Biosciences, Inc.
COURT: U.S. District Court for the District of Massachusetts
PRACTICE AREA: Investor Fraud
STATUS: Investigation
CLASS PERIOD: January 25, 2018 - March 14, 2018

Hagens Berman Sobol Shapiro LLP reminds investors in Solid Biosciences, Inc. (NASDAQ: SLDB) of the May 29, 2018 Lead Plaintiff deadline in the securities class action pending the U.S. District Court for the Northern District of Illinois.

If you purchased or otherwise acquired shares of SLDB pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information, contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018.  In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.

On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy.  This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.

The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.

“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases


Please fill out the form below and we will get back to you as soon as we can.
File Upload *
Additional Information *
Send me: *

Case videos

Case Gallery

Case Timeline

04/04/18: Investigation